biologics have become an important part in the cancer landscape, providing better outcomes for some patients . because they are made from living organisms biologics can not be exactly copied [generics]. the complex manufacturing process of biologics results in high costs. these high costs translates into decreased access for patients.
biosimilars are biologics that are highly similar to biologics. biosimilars have the potential to increase access and create better outcomes for patients all while providing lower cost options for cancer care.
biosimilars are often more cost effective, the savings made from the use of biosimilars can then be allocated to enhancing treatment access to more innovative therapies and providing alternatives for clinicians. however, in order to fully realize the potential of biosimilars, we must work together to ensure proper implementation and adoption into our healthcare system.